Tram brings 30+ years of leadership in business modeltransformation, commercial strategy, and preparing companies for divestiture or sale exits across both public Fortune 50 and private mid to microcap companies from AI & Emerging Tech, MedTech & Digital Health sectors. Builder and connector by nature, she aligns board strategy with shareholder interests,
driving value creation, and navigating high-stakes corporate transactions, strategic market pivots, and international expansion, while mitigating legal and financial risks.

Tram currently serves on the Advisory Board of the Sabi,a US women’s consumer health product innovator, the Advisory Board of Agentic AI platform Rizlum, Luxembourg Private Equity Association’s iNED Steering Committee and the IBA Environmental Health & Safety Law Committee. Through her own firm, Vitanlink, Tram provides strategic board advisory, operating partner services and angel investment. Vitanlink’s partners and clients range from early stages to privately held small & midcap, publicly traded Fortune 500 companies and Private Equity Venture Capital and family office funds.

Over the past three decades, Tram has served in 3 capacities as a board-level executive, board director and board advisor in publicly traded, family-owned and private equity and venture-backed environments within health and deep technology sectors. Most recently she advised a pan-European private equity-owned diagnostic fund portfolio company on go-to-market strategy, risk mitigation, and shareholder alignment.

Prior to starting herfirm, Tram was the CEO of Welch Allyn France [NYSE: BAX from 2021] and a member of the EMEA Europe Middle East and Africa Executive Management Board, a $1B family-owned primary care vital signs and monitoring. Tram’s clients included health system providers, long-term care groups, group purchasing organizations and medical distributors. She led the company’s commercial and organizational transformation, enabling a $2.05B sale to Hill-Rom (2015).

Earlier in her career,Tram served as the J&J Ortho-Clinical Diagnostic EMEA Europe Middle East and Africa Management Board member, focused on marketing strategy and international markets. Her leadership skills were instrumental in building a market and profitability-focused strategy, leading to the EBIT uplift and a $4.0–$4.15B divestiture to Carlyle (2014). She was awarded the Johnson & Johnson Standards of Leadership recognition twice.

Education & Certifications

MBA – McGill University, Canada

LL.M, International Financial Law – King’s College London, UK

CPA Certified Public Accountant – New Hampshire State, US

Non-Executive Director Diploma – Financial Times Pearson, UK

Private Company Governance Certification – PDA, US

Global Perspectives

Languages: French (native), English (fluent), Vietnamese and German (conversational).

Lived/worked in 15+ cities across North America, Europe, and Asia.

Multicultural agility on international boards.

Recognition

✔ Top Healthcare Mentor (9+/10) – Endeavor Global Network

✔ Featured in Korn Ferry’s The Five Disciplines of Inclusive Leaders (2020)

✔ Standards of Leadership Awards – Johnson & Johnson (2002, 2005)

"Tram is a bright, highly educated, and flexible businesswoman, capable of leading with integrity and servant leadership." — CEO & Board Member, former Executive Vice President in Fortune 500